LivaNova (LIVN) Expected to Announce Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is expected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $1.06 per share and revenue of $381.10 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. The firm had revenue of $390.59 million during the quarter, compared to analysts’ expectations of $380.50 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.05 EPS. On average, analysts expect LivaNova to post $3.78 EPS for the current fiscal year and $4.16 EPS for the next fiscal year.

LivaNova Price Performance

Shares of LivaNova stock opened at $78.97 on Monday. The firm has a market capitalization of $4.35 billion, a PE ratio of 23.36 and a beta of 0.91. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. LivaNova has a 12 month low of $48.82 and a 12 month high of $85.76. The business’s 50-day moving average price is $78.49 and its 200-day moving average price is $72.91.

Analysts Set New Price Targets

LIVN has been the subject of several research reports. Needham & Company LLC upped their target price on LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a research report on Wednesday, August 5th. Zacks Research downgraded shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Mizuho lifted their price target on shares of LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Finally, Weiss Ratings upgraded shares of LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $87.75.

Insider Buying and Selling

In related news, Director Brooke Story sold 2,300 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the transaction, the director owned 7,488 shares in the company, valued at $609,672.96. This represents a 23.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Francesco Bianchi sold 3,500 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the completion of the sale, the director directly owned 4,434 shares of the company’s stock, valued at $345,896.34. The trade was a 44.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 7,450 shares of company stock valued at $591,839. 0.35% of the stock is owned by corporate insiders.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.